Long‐acting beta2‐agonists vs placebo
Severe exacerbations requiring hospitalisation over the study period · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower severe exacerbations (hospitalisations) compared with placebo (moderate certainty).
1 finding from 1 review
- Long‐acting beta₂‐agonists for chronic obstructive pulmonary disease 2013 · Cochrane Headline outcomes onlyOR 0.73 [0.56, 0.95]7 studies · 2859 participantsModerate